share_log

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

银屑病试验中Piclidenoson数据公布后，Can-Fite BioPharma股价跳涨
Benzinga Real-time News ·  2022/06/29 19:50
  • Can-Fite BioPharma Ltd (NYSE:CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
  • The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses. 
  • At week 16, patients receiving Piclidenoson 3mg demonstrated statistically significant improvement compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response - Piclidenoson 3mg: 9.7% vs. placebo: 2.6%. 
  • Related: Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study.
  • Secondary endpoint parameters at week 32 comparing Piclidenoson to the active control drug, Amgen Inc's (NASDAQ:AMGN) Otezla (apremilast), revealed inferiority related to PASI 75 (17% vs. 26.2%) and PASI 50 (34.1% vs. 49.5%).
  • But revealed the superiority of Piclidenoson compared to Otezla in the Psoriasis Disability Index (PDI) (20.5% vs. 10.3%).
  • Piclidenoson showed a favorable safety profile.
  • Price Action: CANF shares are up 33.8% at $1.19 during the premarket session on the last check Wednesday.
  • 凯菲特生物制药有限公司(纽约证券交易所市场代码：CANF)宣布了在400多名患有中到重度斑块状牛皮癣的成年人身上进行的Piclidenoson Comfort 3期试验的TOPLINE结果。
  • 研究数据显示，每日两次口服2毫克或3毫克匹立地松的患者在临床上具有相同的疗效。
  • 在第16周，服用3毫克匹利地松的患者与服用安慰剂的患者相比，表现出统计上的显著改善，根据牛皮癣面积和严重程度指数(PASI)75反应--匹利地松3毫克：9.7%对安慰剂：2.6%。
  • 相关： 从银屑病研究中读取Piclidenoson数据时，Can-Fite BioPharma标记延迟.
  • 在第32周比较匹利地松和活性对照药物的次要终点参数，安进纳斯达克：AMGN)Otezla(Apremilast)，显示出与PASI75(17%对26.2%)和PASI50(34.1%对49.5%)相关的劣势。
  • 但与Otezla相比，Piclidenoson在牛皮癣残疾指数(PDI)中的优势(20.5%比10.3%)。
  • Piclidenoson显示出良好的安全性。
  • 价格行动：在周三的盘前交易中，CANF的股价上涨了33.8%，至1.19美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发